摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid | 528848-55-7

中文名称
——
中文别名
——
英文名称
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid
英文别名
2-[7-Tert-butyl-3-(4-chlorophenyl)-2,5-dioxo-1,3-dihydro-1,4-benzodiazepin-4-yl]-2-phenylacetic acid
[7-tert-Butyl-3-(4-chloro-phenyl)-2,5-dioxo-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl]-phenyl-acetic acid化学式
CAS
528848-55-7
化学式
C27H25ClN2O4
mdl
——
分子量
476.959
InChiKey
XGKRZUYJIOBZQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    86.7
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • [EN] SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER<br/>[FR] 1,4-BENZODIAZEPINES SUBSTITUEES ET LEURS UTILISATIONS POUR LE TRAITEMENT DU CANCER
    申请人:DIMENSIONAL PHARM INC
    公开号:WO2003041715A1
    公开(公告)日:2003-05-22
    The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently -C(O)-, CH2- or -C(S)-; R?1, R2, R3, R4, R7, R8, Rb, Rc, Rd¿ and M are defined herein, R5 is hydrogen, alkyl cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R10 is -(CH¿2?)n-CO2R?b¿, -(CH¿2?)m-CO2M, -(CH2)i-OH or -(CH2)j-CONR?cRd¿ n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
    本发明涉及新型1,4-平类化合物、其制药组合物以及作为HDM2-p53相互作用抑制剂的用途。化合物具有式(I)或其溶剂化物、合物或药学上可接受的盐;其中:X和Y独立地为-C(O)-、CH2-或-C(S)-;R?1、R2、R3、R4、R7、R8、Rb、Rc、Rd¿和M的定义如本文所述,R5为、烷基环烷基、可选取代芳基、可选取代杂环芳基、可选取代芳基烷基、可选取代杂环芳基、羧基烷基、烷羧酸、烷羧酸烷基、基甲酰基、基甲酰基烷基、烷基基甲酰基或烷基基甲酰基烷基;R6为环烷基、芳基、杂环芳基、环烷基烷基、芳基烷基、杂环芳基烷基或饱和或部分不饱和杂环,每个都可以取代;R9为环烷基、芳基、杂环芳基、饱和或部分不饱和杂环、环烷基(烷基)、芳基烷基或杂环芳基烷基,每个都可以取代;R10为-( )n-CO2R?b¿、-( )m-CO2M、-( )i-OH或-( )j-CONR?cRd¿,其中n为0-8,m为0-8,i为1-8,j为0-8。
  • Substituted 1,4-benzodiazepines and uses thereof
    申请人:——
    公开号:US20030109518A1
    公开(公告)日:2003-06-12
    The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: X and Y are independently —C(O)—, —CH 2 — or —C(S)—; R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R b , R c , R d and M are defined herein; R 5 is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl; R 6 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; R 9 is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and R 10 is —(CH 2 ) n —CO 2 R b , —(CH 2 ) m —CO 2 M, —(CH 2 ) i —OH or —(CH 2 ) j —CONR c R d n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
    本发明涉及新型1,4-平化合物,其药物组合物以及作为HDM2-p53相互作用抑制剂的用途。化合物具有公式I:1或其溶剂化物,合物或药学上可接受的盐;其中:X和Y独立地为—C(O)—,—CH2—或—C(S)—;R1、R2、R3、R4、R7、R8、Rb、Rc、Rd和M在此定义;R5为,烷基,环烷基,可选取代芳基,可选取代杂环芳基,可选取代芳基烷基,可选取代杂环芳基烷基,羧基烷基,烷羰基,烷羰基烷基,基羰基,基羰基烷基,烷基基羰基或烷基基羰基烷基;R6为环烷基,芳基,杂环芳基,环烷基烷基,芳基烷基,杂环芳基烷基或饱和或部分不饱和杂环,每个都可以选择性地取代;R9为环烷基,芳基,杂环芳基,饱和或部分不饱和杂环,环烷基(烷基),芳基烷基或杂环芳基烷基,每个都可以选择性地取代;R10为—( )n—CO2Rb,—( )m—CO2M,—( )i—OH或—( )j—CONRcRd,其中n为0-8,m为0-8,i为1-8,j为0-8。
  • SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER
    申请人:3-DIMENSIONAL PHARMACEUTICALS, INC.
    公开号:EP1443937A1
    公开(公告)日:2004-08-11
  • US7067512B2
    申请人:——
    公开号:US7067512B2
    公开(公告)日:2006-06-27
查看更多